{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:54:48Z","timestamp":1784231688841,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jaad.2020.05.143","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T11:25:18Z","timestamp":1591097118000},"page":"1227-1239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes: A systematic review"],"prefix":"10.1016","volume":"85","author":[{"given":"Claire R.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Algu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhshan","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron F.","family":"Leveille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khizar","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Rae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.05.143_bib1","first-page":"1","article-title":"The ambulatory care burden of nail conditions in the United States","volume":"21","author":"Lipner","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"10.1016\/j.jaad.2020.05.143_bib2","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/jdv.13677","article-title":"The prevalence of unsuspected onychomycosis and its causative organisms in a multicenter Canadian sample of 30000 patients visiting physicians' offices","volume":"30","author":"Gupta","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.143_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2710.2009.01107.x","article-title":"Toenail onychomycosis: an important global disease burden","volume":"35","author":"Thomas","year":"2010","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.143_bib4","first-page":"E21","article-title":"Onychomycosis: current and investigational therapies","volume":"94","author":"Lipner","year":"2014","journal-title":"Cutis"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.143_bib5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaad.2018.03.062","article-title":"Onychomycosis: clinical overview and diagnosis","volume":"80","author":"Lipner","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.143_bib6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000469666","article-title":"Patient-reported outcomes in onychomycosis: a review of psychometrically-evaluated instruments in assessing treatment effectiveness","volume":"3","author":"Wang","year":"2017","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.jaad.2020.05.143_bib9","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2020.05.143_bib10","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for\u00a0assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2020.05.143_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-4-50","article-title":"The OnyCOE-t questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis","volume":"4","author":"Potter","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaad.2020.05.143_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF00449429","article-title":"Quality of\u00a0life of persons with onychomycosis","volume":"2","author":"Lubeck","year":"1993","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jaad.2020.05.143_bib13","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S0190-9622(98)70487-6","article-title":"Measuring health-related quality of life in onychomycosis","volume":"38","author":"Lubeck","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.143_bib14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1046\/j.1365-4362.1997.00163.x","article-title":"The effect of toenail onychomycosis on patient quality of life","volume":"36","author":"Elewski","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.05.143_bib15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.7547\/87507315-87-11-512","article-title":"Onychomycosis: baseline results from an observation study","volume":"87","author":"Schein","year":"1997","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1016\/j.jaad.2020.05.143_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2230.1997.tb02626.x","article-title":"The impact of onychomycosis on quality of life","volume":"22","author":"Whittam","year":"1997","journal-title":"Clin Exp Dermatol"},{"issue":"5 pt 1","key":"10.1016\/j.jaad.2020.05.143_bib17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0190-9622(98)70199-9","article-title":"Effect of onychomycosis on quality of life","volume":"38","author":"Drake","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"2 pt 1","key":"10.1016\/j.jaad.2020.05.143_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0190-9622(99)70047-2","article-title":"The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life","volume":"41","author":"Drake","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.143_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/A:1026429012353","article-title":"A health-related quality of life measure for use in patients with\u00a0onychomycosis: a validation study","volume":"8","author":"Lubeck","year":"1999","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jaad.2020.05.143_bib20","first-page":"37","article-title":"Health-related quality of life in patients with toenail onychomycosis: data from a 9-month observational study","volume":"6","author":"Lubeck","year":"1999","journal-title":"J Clin Outcomes Manag"},{"key":"10.1016\/j.jaad.2020.05.143_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/A:1008986826756","article-title":"Measuring the impact of onychomycosis on patient quality of life","volume":"9","author":"Turner","year":"2000","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.143_bib22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1468-3083.2006.02004.x","article-title":"Evaluation of quality of life in patients with toenail onychomycosis by Polish version of an international onychomycosis-specific questionnaire","volume":"21","author":"Szepietwoski","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2020.05.143_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1439-0507.2008.01618.x","article-title":"Stigmatization in onychomycosis patients: a population-based study","volume":"52","author":"Szepietwoski","year":"2009","journal-title":"Mycoses"},{"key":"10.1016\/j.jaad.2020.05.143_bib24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/myc.12072","article-title":"Quality of life in patients with toenail onychomycosis","volume":"56","author":"Milobratovi\u0107","year":"2013","journal-title":"Mycoses"},{"key":"10.1016\/j.jaad.2020.05.143_bib25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4103\/0378-6323.154796","article-title":"Onychomycosis: a study of self recognition by patients and quality of life","volume":"81","author":"Bunyaratavej","year":"2015","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.143_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000504944","article-title":"Impact of onychomycosis on the Quality of Life: Dermatology Life Quality Index-Based Cross-Sectional study","volume":"6","author":"Kayarkatte","year":"2020","journal-title":"Skin Appendage Disord"},{"issue":"6 pt 2","key":"10.1016\/j.jaad.2020.05.143_bib27","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/S0190-9622(98)70492-X","article-title":"Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail","volume":"38","author":"Ling","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.143_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.7547\/87507315-91-3-127","article-title":"Efficacy of terbinafine for toenail onychomycosis: a multicenter trial of various treatment durations","volume":"91","author":"Pollak","year":"2001","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1016\/j.jaad.2020.05.143_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7547\/87507315-91-10-521","article-title":"Patient satisfaction with oral versus nonoral therapeutic approaches in onychomycosis","volume":"91","author":"Stier","year":"2001","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1016\/j.jaad.2020.05.143_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.7547\/87507315-93-5-373","article-title":"Satisfaction with onychomycosis treatment: pulse versus continuous dosing","volume":"93","author":"Warshaw","year":"2003","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1016\/j.jaad.2020.05.143_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/09546630310012109","article-title":"Itraconazole pulse therapy improves the quality of life of patients with toenail onychomycosis","volume":"14","author":"Firooz","year":"2003","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2020.05.143_bib32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/09546630600965004","article-title":"The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis","volume":"18","author":"Potter","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2020.05.143_bib33","first-page":"294","article-title":"Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial","volume":"48","author":"Malay","year":"2009","journal-title":"J Foot Ankle Res"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.143_bib34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/pde.12064","article-title":"Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy","volume":"30","author":"Friedlander","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2020.05.143_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jana.2015.10.004","article-title":"A novel treatment for onychomycosis in people living with HIV infection: Vicks VapoRub\u2122 is effective and safe","volume":"27","author":"Snell","year":"2016","journal-title":"J Assoc Nurses AIDS Care"},{"key":"10.1016\/j.jaad.2020.05.143_bib36","first-page":"25","article-title":"Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life","volume":"7","author":"Tosti","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.143_bib37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s13555-018-0254-1","article-title":"Daily application of an aqueous, acidifying, peelable nail polish versus weekly amorolfine for topical onychomycosis treatment: a prospective, randomized, blinded trial","volume":"8","author":"Eertmans","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"10.1016\/j.jaad.2020.05.143_bib38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/1346-8138.14935","article-title":"Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis including severe cases: a multi-center, single-arm study","volume":"46","author":"Iozumi","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2020.05.143_bib39","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/DSS.0000000000000189","article-title":"A 1,320-nm Nd:YAG laser for improving the appearance of onychomycosis","volume":"40","author":"Ortiz","year":"2014","journal-title":"Dermatol Surg"},{"issue":"2","key":"10.1016\/j.jaad.2020.05.143_bib40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/jdv.13842","article-title":"Methyl aminolevulinate photodynamic therapy for onychomycosis: a multicenter, randomized controlled clinical trial","volume":"31","author":"Gilaberte","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.143_bib41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.05.143_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.jaad.2020.05.143_bib43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7547\/0950264","article-title":"The Bristol Foot Score: developing a patient-based foot-health measure","volume":"95","author":"Barnett","year":"2005","journal-title":"J Am Podiatr Med Assoc"},{"issue":"12","key":"10.1016\/j.jaad.2020.05.143_bib44","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1365-4632.2007.03362.x","article-title":"NailQoL: a quality-of-life instrument for onychomycosis","volume":"46","author":"Warshaw","year":"2007","journal-title":"Int J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2020.05.143_bib45","first-page":"1263","article-title":"Onychomycosis: burden of diseases and the role of topical antifungal treatment","volume":"12","author":"Daniel","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.143_bib46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14656566.2019.1571039","article-title":"Pharmacotherapy for onychomycosis: new and emerging treatments","volume":"20","author":"Lipner","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaad.2020.05.143_bib47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40257-014-0096-2","article-title":"Topical therapy for toenail onychomycosis: an evidence-based review","volume":"15","author":"Gupta","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2020.05.143_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16394","article-title":"Onychomycosis: a review","author":"Gupta","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.143_bib49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jaad.2019.10.078","article-title":"Modeling of usage and estimation of cost for efinaconazole 10% topical solution in the treatment of onychomycosis","volume":"83","author":"Lin","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.143_bib50","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jaad.2019.01.032","article-title":"Pharmacy costs of medications for the treatment of onychomycosis in the United States","volume":"81","author":"Yang","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2020.05.143_bib51","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1586\/17512433.2015.1083418","article-title":"Efinaconazole 10% topical solution for the topical treatment of onychomycosis of the toenail","volume":"8","author":"Lipner","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jaad.2020.05.143_bib52","first-page":"89","article-title":"Evaluation of the appearance of nail polish following daily treatment of ex\u00a0vivo human fingernails with topical solutions of tavaborole or efinaconazole","volume":"15","author":"Vlahovic","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.05.143_bib53","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jaad.2018.05.1260","article-title":"Onychomycosis: treatment and prevention of recurrence","volume":"80","author":"Lipner","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2020.05.143_bib54","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/jdv.14212","article-title":"A critical review of improvement rates for laser therapy used to treat toenail onychomycosis","volume":"31","author":"Gupta","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"suppl 65","key":"10.1016\/j.jaad.2020.05.143_bib55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2133.149.s65.5.x","article-title":"Onychomycosis in clinical practice: factors contributing to recurrence","volume":"149","author":"Scher","year":"2003","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2020.05.143_bib56","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1185\/03007995.2016.1147026","article-title":"Onychomycosis: a small step for quality of care","volume":"32","author":"Lipner","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.jaad.2020.05.143_bib57","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jamadermatol.2016.0785","article-title":"Confirmatory testing for onychomycosis","volume":"152","author":"Lipner","year":"2016","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220310203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220310203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:01:03Z","timestamp":1759273263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220310203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0190962220310203"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.143","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}